Category Archives: RXDX-101 – entrectinib – by Ignyta

Ignyta ASCO update for RXDX-101

11 patients with ALK+ treated (not all NSCLC). 7 patients with ROS1 treated. Treatment is an oral pill. The previous statement made about the treatment involving an IV infusion was wrong. However the fact that patients only received treatment for … Continue reading

Posted in Lung cancer, Neuroblastomas, Research, RXDX-101 - entrectinib - by Ignyta | Leave a comment

Abstracts from upcoming ASCO conference

Overall, I would say the results were disappointing, fewer patients had progressed far enough for meaningful results than I had hoped for. However, given that the data cut offs were usually around December and most of the trials were near … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, RXDX-101 - entrectinib - by Ignyta, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

List of 9 ALK Inhibitors

List of 9 ALK inhibitor drugs currently in clinical trials: FDA approved (but several trials ongoing) Novartis – Ceritinib Pfizer – Crizotinib FDA Breakthrough Status Chugai – Alectinib (filed NDA in Japan) Ongoing trials Ariad AP26113 Nerviano NMS-E628. (Licensed by … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, CEP-37440, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, NMS-E628, Potential Treatments, Regulatory applications & approvals, Research, RXDX-101 - entrectinib - by Ignyta, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

Clinical trial results to be announced at ASCO 2014 (5/30 to 6/3)

Updated efficacy and safety of the ALK inhibitor AP26113 in patients with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). (Abstract 8047) Antitumor activity of alectinib (CH5424802/RO5424802) for ALK-rearranged NSCLC with or without prior crizotinib treatment in bioequivalence study. … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Lung cancer, Potential Treatments, RXDX-101 - entrectinib - by Ignyta, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

List of drugs in clinical trials

List of 10 ALK inhibitor drugs currently (or soon to be) in clinical trials: Ariad AP26113 Astellas ASP-3026 Chugai Alectinib (filed NDA in Japan) Nerviano NMS-E628. (Licensed by Ignyta and renamed RXDX-101) Novartis LDK-378 Pfizer Crizotinib (FDA approved but several … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, CEP-37440, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, NMS-E628, Potential Treatments, Research, RXDX-101 - entrectinib - by Ignyta, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment